Elacestrant: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

21 May 2024

  • curprev 00:1200:12, 21 May 2024‎ Rithish Nimmagadda talk contribs‎ 3,173 bytes +313‎ No edit summary
  • curprev 00:0900:09, 21 May 2024‎ Rithish Nimmagadda talk contribs‎ 2,860 bytes +2,860‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=elacestrant |aOrAn=an |drugClass=estrogen receptor antagonist |indicationType=treatment |indication=estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer that has progressed following ≥1 line of endocrine-based therapy in postmenopausal women or adult men. |fdaLIADAdult=Dosage of elacestrant hydro..."
Retrieved from "https://www.wikidoc.org/index.php/Elacestrant"